Skip to main navigation
Logo

Investors

Press Releases

Date Title View
November 9, 2022
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 2, 2022
AN2 Therapeutics to Present at Upcoming Investor Conferences
October 19, 2022
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
October 6, 2022
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
September 29, 2022
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
August 29, 2022
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 11, 2022
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
June 29, 2022
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
May 10, 2022
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 9, 2022
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 16

Shareholder Tools

Print Page
Email Alerts
RSS Feeds
Investor Contact
  • Investor Overview
  • News & Events
    • Press Releases
    • Events
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Committee Composition
  • Financial Information
    • SEC Filings
  • IR Resources
    • Email Alerts
    • Contact IR
  • More
    • About Us
      • Mission
      • Leadership
      • Board of Directors
      • Founders
      • Partners
      • Expanded Access Policy
    • Technology
    • Pipeline
      • Epetraborole
      • NTM
    • Investors
      • Investor Overview
      • News & Events
        • Press Releases
        • Events
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Committee Composition
      • Financial Information
        • SEC Filings
      • IR Resources
        • Email Alerts
        • Contact IR
    • Careers
      • Job Opportunities
      • Values
      • Benefits
    • Contact
    • Home
    • About Us
      • Mission
      • Leadership
      • Board of Directors
      • Founders
      • Partners
      • Expanded Access Policy
    • Technology
    • Pipeline
      • Epetraborole
      • NTM
    • Investors
      • Investor Overview
      • News & Events
        • Press Releases
        • Events
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Committee Composition
      • Financial Information
        • SEC Filings
      • IR Resources
        • Email Alerts
        • Contact IR
    • Careers
      • Job Opportunities
      • Values
      • Benefits
    • Contact
    • Privacy Policy
    • Terms of Use
    Logo

    Location
    1800 El Camino Real, Suite D
    Menlo Park, CA 94027
    Phone: 650-331-9090

    General Information
    info@an2therapeutics.com

    Investor & Media Inquiries
    info@an2therapeutics.com

    Job Inquiries
    careers@an2therapeutics.com

    Business Development Contact
    partner@an2therapeutics.com

    linkedin

    • Privacy Policy
    • Terms of Use
    © 2023 AN2 Therapeutics All rights reserved.
    Website Design: Hane Chow, Inc.